Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GNC-035 in relapsed/refractory hematologic malignancies
NCT05104775Phase 1Active, not recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Feb 2022
- Primary completion
- Dec 2025
- Modality
- Prophylactic Vaccines, Multispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GNC-035 in non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), B-cell acute lymphoblastic leukemia (B-ALL) and 1 more, sponsored by Biokin Pharmaceutical. Primary endpoints: Dose-Limiting Toxicity at 2 weeks, Maximum Tolerated Dose at 2 weeks and 4 more. Started Feb 2022; status: active, not recruiting.
02
Drugs
GNC-035
03
Conditions
non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia (CLL)B-cell acute lymphoblastic leukemia (B-ALL)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05104775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05104775.